Skip to main content

Oliver FitzGerald

Oliver FitzGerald is a consultant rheumatologist and Newman Clinical Research Professor at St Vincent's University Hospital and the Conway Institute, University College Dublin (UCD). Professor FitzGerald has published over 250 peer-reviewed papers, many on the subject of spondyloarthropathy. His main research interests include clinical and therapeutic studies; the development of novel imaging techniques; analysis of synovial and skin cellular and cytokine profiles; and, more recently, studies of gene and protein expression in diseased tissue. He currently receives research funding support from the Health Research Board and a number of pharmaceutical companies.

Latest contributions from Oliver FitzGerald

01-03-2019 | Osteoarthritis | Highlight | Article

Early-onset osteoarthritis in association with familial angel-shaped phalango-epiphyseal dysplasia previously referred to as peripheral dysostosis

Editorial board member Oliver FitzGerald presents a family with two siblings having features consistent with angel-shaped phalango-epiphyseal dysplasia (ASPED), and a mother with a normal phenotype but with severe, early-onset multi-joint osteoarthritis.

31-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | Article

From the Editorial Board: Highlights from the 2018 ACR/ARHP Annual Meeting

Editorial board members Oliver FitzGerald and Fernando Pérez-Ruiz provide their highlights from the spondyloarthropathy and crystal arthropathy sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

19-12-2017 | Medications | Editorial | Article

Managing antirheumatic medication in patients undergoing elective arthroplasty

Editorial Board member Oliver FitzGerald reviews the recent guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty.

08-06-2017 | NSAIDs | Editorial | Article

Cardiovascular risk of non-steroidal anti-inflammatory drugs

Editorial Board member Oliver FitzGerald reviews the cardiovascular risk of non-steroidal anti-inflammatory drugs such as celecoxib, naproxen, and ibuprofen in light of results from the PRECISION study.

Image Credits